China cut cancer-drug prices by covering the rich, not by targeting subsidies at the poor

the problem

Making expensive new drugs affordable on a limited government budget, when the standard fix -- narrowly means-tested coverage for those who can't pay -- gives the government no real leverage to negotiate lower prices with drugmakers in the first place

background

what everyone would do

Means-test drug insurance narrowly, subsidizing coverage only for patients who genuinely can't afford full price -- the standard, seemingly efficient way to stretch a limited government budget, since covering wealthier patients who could pay full price themselves looks like an unnecessary subsidy leak.

what they saw

The reform's designers saw that a small, guaranteed pool of only poor, subsidized patients gives a government negotiator almost no leverage over a drugmaker, since the supplier has little to lose by refusing to cut prices for a market it barely needs. Bringing wealthier, less price-sensitive households into the same insurance pool wasn't a subsidy leak, it was the actual source of bargaining power -- a bigger, more committed national buyer had something to threaten a manufacturer with that a narrow pool never could.

the move

The reform paired two mechanisms that only work together: government negotiators centrally set prices for innovative drugs across the whole national market, while expanded insurance coverage -- including for wealthier households who could otherwise pay full price -- built a larger, more committed pool of buyers into the negotiation. A larger buyer pool that included price-insensitive wealthy patients gave China's negotiators real leverage over drugmakers that a narrow pool of only poor, subsidized patients could never generate, because a supplier has little incentive to cut prices for a small, guaranteed buyer group with nowhere else to go.

why it works

Because centralized negotiation without a large insured buyer pool gives drugmakers no reason to cut prices (firms have no gain from trade relative to just selling at full price on the open market) and insurance expansion without negotiation just lets firms raise prices in response to reduced consumer price sensitivity, the two policies only worked in combination -- insurance alone produced a 5-point gain in innovative-drug market share, negotiation alone produced zero, but the combined reform produced an 18-point gain, more than the sum of either alone. Including higher-income households in the pool specifically amplified the government's leverage, which is why the researchers found social welfare is maximized by a moderately regressive insurance schedule: the wealthy's inclusion is what let poorer patients access the same negotiated low price.

the payoff

Economists Panle Jia Barwick, Ashley Swanson and Tianli Xia, analyzing SinoHealth sales data from 2017-2023 focused on cancer drugs, found the reform reduced retail prices by 48% for successfully negotiated drugs (a later NBER Digest summary of a revised draft reported 57%) while 25-36% of negotiations failed outright; out-of-pocket costs for successfully negotiated drugs fell 80-89%, drug utilization rose 350%, and the reform increased the market share of innovative drugs among all cancer drugs by 18 percentage points (1,133%) -- far exceeding what insurance expansion alone would have produced (5 points, 295%) or price negotiation alone (0 points, since firms had no reason to negotiate against a guaranteed pool with no other buyers). The combined reform generated an estimated ¥40 billion ($5.6 billion) in annual consumer surplus and roughly 900,000 additional patient life-years per year, while firms still captured about two-thirds of the negotiation surplus for themselves.

where it breaks

This mechanism depends on the negotiator genuinely representing enough aggregate demand that a supplier has real gains from trade to lose by refusing to negotiate -- a buying pool too small or fragmented relative to the supplier's other markets gives no comparable leverage. It also has a real distributional cost worth weighing deliberately: the paper's own finding that firms still captured roughly two-thirds of the negotiation surplus, and that failed negotiations (25-36% of cases) left some drugs unavailable at any reimbursed price, shows the leverage generated by pooling isn't unlimited, and the approach requires a credible way to actually exclude non-negotiating suppliers from the pooled market, or firms retain the option of ignoring the negotiation entirely.

what came after

The paper's authors note that price negotiation without insurance expansion would have had no effect at all -- firms had no incentive to negotiate down prices for a market they weren't gaining new access to -- while insurance expansion without negotiation would have simply let firms raise retail prices in response to reduced consumer price sensitivity; the researchers find social welfare is actually maximized by a moderately regressive insurance schedule, since demand expansion from higher-income households is precisely what gives government negotiators their bargaining leverage.

references

1. [1]A Double Dose of Reform: Insurance and Centralized Negotiation in Drug MarketsNBER Working Paper 33832 (Panle Jia Barwick, Ashley T. Swanson, Tianli Xia), 2025panlebarwick.github.io
2. [2]China's Expansion of Drug Insurance Increased Access While Containing CostsNBER Digest, 2025nber.org

keep it

same kind of clever

• 1970 · AldiAldi didn't hire staff to chase abandoned shopping carts across the parking lot — it made getting a quarter back the customer's own problem to solve.
• 1999 · BBK Electronics (步步高, Duan Yongping)Rather than run three growing product lines as divisions that would eventually compete for the same budget and shelf space, Duan Yongping split them into fully separate companies — two of which, OPPO and vivo, are now each other's biggest rivals.
• 1995 · City of Bogotá (Mayor Antanas Mockus)Bogotá answered jaywalking and reckless driving with mimes instead of more tickets